Company Snapshot

Investment Thesis

Illumina is the market leader in DNA sequencing instruments and consumables, powering population genomics, oncology testing, and research applications worldwide.

  • NovaSeq X Ramp: NovaSeq X systems deliver threefold throughput improvements, reducing the cost per genome and refreshing the high-throughput installed base.
  • Clinical Adoption: Companion diagnostics and oncology partnerships drive sequencing deeper into routine care.
  • Focused Portfolio: Following the GRAIL divestiture process, Illumina is refocusing capital on core sequencing innovation.

Sequencing Footprint

Installed Base 20,000+ sequencing instruments deployed across research labs and hospitals
Consumables Mix Reagents and flow cells provide recurring revenue tied to instrument utilization
Population Genomics Large national genome programs rely on Illumina for scale and accuracy
Partner Ecosystem Expansive partnerships with diagnostics, pharma, and analytics companies

Statistics from Illumina 2024 earnings materials and industry disclosures.

Recent Performance

MTD -1.86%
QTD +18.56%
YTD -7.40%
5Y -59.93%

Shares remain under pressure as research funding normalizes, but NovaSeq X demand and cost discipline underpin a pathway back to growth.

Strategic Insights

Cost Leadership

NovaSeq X drives sequencing costs lower, expanding addressable use cases for researchers and clinicians.

Clinical Penetration

Oncology, reproductive health, and rare disease testing continue to shift toward sequencing-based diagnostics.

Data & Informatics

Illumina's informatics partnerships help customers manage expanding genomic datasets efficiently.

Latest Coverage

Curated headlines sourced from Maxim’s AI newsroom.

Loading latest coverage...